Molecular tools to understand cellular mRNA demethylation
了解细胞 mRNA 去甲基化的分子工具
基本信息
- 批准号:10026274
- 负责人:
- 金额:$ 24.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAntineoplastic AgentsBase PairingBindingBiochemicalBiologicalBrainBreastCell ProliferationCell SurvivalCellsCervicalChemicalsCollaborationsDataDiseaseDisease ProgressionDrug TargetingEnzymatic BiochemistryEnzymesEventFatty acid glycerol estersGlioblastomaGoalsHumanLinkMalignant NeoplasmsMalignant neoplasm of brainMammalian CellMapsMass Spectrum AnalysisMediatingMesotheliomaMessenger RNAMethylationModificationMolecularMolecular ProbesMusMutationObesityPhasePlayProteinsRNARNA CapsRNA methylationRNA-Binding ProteinsReaderRegulationRoleShapesSiteStomachStructureSurfaceTestingTherapeuticThermodynamicsTranscriptTransfer RNAUniversitiesWorkX-Ray Crystallographyanalogbasecell growthcell typedemethylationembryonic stem cellexperimental studyhuman diseaseleukemiamRNA cappingmalignant breast neoplasmnovel strategiesnucleotide analogstem cell differentiationstem cellsstructured datatherapeutic targettooltranscriptometranscriptome sequencingtumor progression
项目摘要
PROJECT SUMMARY / ABSTRACT
Methyl modifications on mRNA are essential for mammalian cell fate decisions and have recently been shown
to play important roles in the progression of many human cancers. The demethylase FTO, which erases
abundant N6-methyladenosine modifications to dynamically regulate mRNA methylation, is linked to initiation
and progression of cancers including brain, breast, gastric, cervical, mesothelioma, and leukemia. Recent work
has shown that inhibition of FTO suppresses tumor progression in glioblastoma, the most common and deadliest
form of brain cancer, suggesting FTO and other mRNA-modifying enzymes may be promising anti-cancer drug
targets. However, we lack a mechanistic understanding of how FTO targets its modified mRNA substrates,
impacts mRNA function, and contributes to disease progression. Our long-term goal is to define the biochemical,
structural, and molecular mechanisms that regulate mRNA demethylation in the cell, and to develop the new
tools and understanding needed to characterize demethylation activity across the transcriptome and in diverse
human disease states. The work outlined in this proposal will: (1) define the structural and biochemical basis of
FTO target selectivity at the atomic level using X-ray crystallography and enzymology with synthetic modified
nucleotide analogs, (2) generate bioorthogonal chemical probes that covalently trap FTO-installed demethylation
intermediates to directly map sites of demethylation on mRNA, and (3) explore the molecular mechanisms
through which FTO-installed demethylation intermediates may directly regulate mRNA function. This work is
impactful and significant because it will advance the field’s understanding of how methyl eraser FTO is targeted
to different mRNA modifications and how unexplored, metastable intermediate modifications installed during
FTO-mediated demethylation impact mRNA function. Furthermore, the tools we develop to trap demethylation
intermediates will be critical to map sites of mRNA demethylation across the transcriptome in different cell types
and disease states, which will allow our lab and others to directly assess the role of mRNA demethylation in
human cancers linked to FTO function.
项目摘要/摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Scott Mugridge其他文献
Jeffrey Scott Mugridge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Scott Mugridge', 18)}}的其他基金
Administrative supplement to purchase a MerMade 4 oligonucleotide synthesizer for the large-scale production of modified RNA substrates
购买 MerMade 4 寡核苷酸合成仪用于大规模生产修饰 RNA 底物的行政补充
- 批准号:
10797873 - 财政年份:2021
- 资助金额:
$ 24.07万 - 项目类别:
Selectivity and regulation of mRNA demethylation by iron-dependent dioxygenases
铁依赖性双加氧酶对 mRNA 去甲基化的选择性和调节
- 批准号:
10438887 - 财政年份:2021
- 资助金额:
$ 24.07万 - 项目类别:
Selectivity and regulation of mRNA demethylation by iron-dependent dioxygenases
铁依赖性双加氧酶对 mRNA 去甲基化的选择性和调节
- 批准号:
10620782 - 财政年份:2021
- 资助金额:
$ 24.07万 - 项目类别:
Selectivity and regulation of mRNA demethylation by iron-dependent dioxygenases
铁依赖性双加氧酶对 mRNA 去甲基化的选择性和调节
- 批准号:
10276549 - 财政年份:2021
- 资助金额:
$ 24.07万 - 项目类别:
Structural basis of mRNA decapping by Dcp2: conformational changes & co-activator
Dcp2 mRNA 脱帽的结构基础:构象变化
- 批准号:
8607845 - 财政年份:2013
- 资助金额:
$ 24.07万 - 项目类别:
Structural basis of mRNA decapping by Dcp2: conformational changes & co-activator
Dcp2 mRNA 脱帽的结构基础:构象变化
- 批准号:
8456674 - 财政年份:2013
- 资助金额:
$ 24.07万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 24.07万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 24.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 24.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 24.07万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 24.07万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 24.07万 - 项目类别:














{{item.name}}会员




